A TNM-based clinical staging system of ocular adnexal lymphomas.
Abstract: * Context.--The ocular adnexal lymphomas (OAL) arise in the conjunctiva, orbit, lacrimal gland, and eyelids. To date, they have been clinically staged using the Ann Arbor staging system, first designed for Hodgkin and later for nodal, non-Hodgkin lymphoma. The Ann Arbor system has several shortcomings, particularly when staging extranodal non-Hodgkin lymphomas, such as OAL, which show different dissemination patterns from nodal lymphomas.

Objective.--To describe the first TNM-based clinical staging system for OAL.

Design.--Retrospective literature review.

Results.--We have developed, to our knowledge, the first American Joint Committee on Cancer-International Union Against Cancer TNM-based staging system for OAL to overcome the limitations of the Ann Arbor system. Our staging system defines disease extent more precisely within the various anatomic compartments of the ocular adnexa and allows for analysis of site-specific factors not addressed previously. It aims to facilitate future studies by identifying clinical and histomorphologic features of prognostic significance. This system is for primary OAL only and is not intended for intraocular lymphomas.

Conclusions.--Our TNM-based staging system for OAL is a user-friendly, anatomic documentation of disease extent, which creates a common language for multicenter and international collaboration. Data points will be collected with the aim of identifying biomarkers to be incorporated into the staging system.

(Arch Pathol Lab Med. 2009;133:1262-1267)
Article Type: Report
Subject: Non-Hodgkin's lymphomas (Diagnosis)
Non-Hodgkin's lymphomas (Development and progression)
Tumor staging (Methods)
Clinical pathology (Research)
Authors: Coupland, Sarah E.
White, Valerie A.
Rootman, Jack
Damato, Bertil
Finger, Paul T.
Pub Date: 08/01/2009
Publication: Name: Archives of Pathology & Laboratory Medicine Publisher: College of American Pathologists Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 College of American Pathologists ISSN: 1543-2165
Issue: Date: August, 2009 Source Volume: 133 Source Issue: 8
Topic: Event Code: 310 Science & research
Geographic: Geographic Scope: United States Geographic Code: 1USA United States
Accession Number: 230247114
Full Text: By definition, ocular adnexal lymphomas (OALs) arise in the conjunctiva, the orbit, the lacrimal gland, or the eyelids. These tumors can be solitary or multicentric, unilateral or bilateral. They can invade bone, sinuses, nasopharynx, and the cranial cavity. Dissemination can occur to ipsilateral and/or contralateral regional lymph nodes as well as to more distant nodes centrally and peripherally (eg, para-aortic and popliteal nodes). Ocular adnexal lymphomas are mostly extranodal non-Hodgkin lymphomas (NHLs), with the most common subtype being the extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, (1-7) according to the latest World Health Organization lymphoma classification. (8) Although rare, T/NK-cell lymphomas also arise in the ocular adnexa. (9,10) As with other extranodal marginal zone B-cell lymphomas, recurrences occur commonly within the ocular adnexa and other extra-nodal sites, such as salivary glands. Treatment is largely based on radiotherapy with or without systemic chemotherapy and/or immunotherapy, according to clinical staging and histologic subtyping. The 10-year, disease-specific mortality, which varies according to lymphoma subtype, is approximately 5% to 10%. (5)

To date, the most widely used staging system for malignant lymphomas is the Ann Arbor staging system, which was first used for Hodgkin disease in 1971. (11) Although its utility for the staging of other lymphomas has been challenged, the modified Ann Arbor system (12) remains the primary means for determining clinical stage of patients with both nodal and extranodal NHL. Ann Arbor staging is essentially an anatomic assessment of disease that also takes into account any systemic symptoms. It divides the disease extent into 4 stages (stages IIV), according to lymph node group involvement above and below the diaphragm and with or without involvement of organs, such as the spleen, liver, and bone marrow. Other staging systems have been developed for extranodal lymphomas at other sites, such as skin and gastric mucosa. In addition, other prognostic indices have been devised, taking into account features such as age, serum lactate dehydrogenase levels, and the general condition of the patient. These systems supplement the Ann Arbor staging classification to enhance treatment planning and patient stratification in clinical trials.

MATERIALS AND METHODS

The Ann Arbor staging system has a number of shortcomings, particularly when staging extranodal NHLs, such as OALs, which essentially show different dissemination patterns from nodal lymphomas. As with other locations of extranodal lymphoma (eg, gastrointestinal lymphomas), (13) the Ann Arbor staging system is not ideal for documenting the specific, relevant features of primary OAL. The reasons for this include the following:

1. Disproportionate Staging Distribution.--Two-thirds of primary OALs present as a localized mass, which, according to the Ann Arbor system, would be categorized and recorded as a stage IE tumor (E, extranodal; Figure 1). (2,4,6,14-17) Consequently, there is a disproportionately high number of patients in stage IE, whose prognosis cannot be consistently distinguished from each other on either clinical or histomorphologic criteria.

2. Anatomic Location.--Lymphomas occurring in particular locations within the ocular adnexa are associated with an increased risk of disseminated disease. (18) For example, lymphomas occurring in the eyelid or orbit with lacrimal gland involvement are associated with a worse prognosis. (18,19) Within the subgroup of conjunctival lymphomas, systemic disease is more common in patients with lymphomas located at an extralimbal site (ie, in the fornix or midbulbar region). (20) Furthermore, some evidence suggests that whether the lymphoma is located predominantly in the anterior or posterior orbit is of prognostic significance (J.R., unpublished data, 2008). (21) Lymphomatous involvement of the extraocular muscles has been demonstrated by some to be a poor prognostic factor. (22) Currently, all OALs confined to the ocular adnexa are categorized and recorded by the Ann Arbor system as stage IE, whatever their exact location or size. This system, therefore, does not discriminate between patients with high-risk or low-risk stage IE.

3. Extent of Primary Tumor Infiltration.--New imaging techniques enable a more precise definition of tumor extent. (23,24) This feature cannot be documented adequately using the Ann Arbor staging system.

4. Multiple Tumors.--Ocular adnexal lymphomas can occur as multiple tumors within the same site, for example, in the conjunctiva. Large studies show that such multiple conjunctival tumors are associated with a worse prognosis. (20) There is no allowance for the staging of multiple tumors in the Ann Arbor classification.

5. Lymph Node Involvement.--Recent studies indicate that conjunctival OAL with nodal involvement is associated with a worse prognosis. (25) Currently, the Ann Arbor system categorizes lymph node involvement by OAL as stage II or stage III. This information, however, is vague, and could be made more precise by documenting, first, whether any regional lymph node involvement is ipsilateral or contralateral and, second, whether any distant lymph nodes are affected, as indicated below.

6. Multicentricity and Bilaterality of OAL.--Ocular adnexal lymphomas can occur in separate noncontiguous sites in the ocular adnexa (eg, concurrent but noncontiguous conjunctival and orbital tumors). Such multiple tumors can be either ipsilateral or, in up to 15% of cases, bilateral. Presently, both of these would be staged and recorded as IE, using the Ann Arbor staging system.

7. Noncontiguous Involvement of Tissues External to the Ocular Adnexa.--Commonly, OALs are associated with concurrent involvement of extranodal sites, such as the parotid and submandibular glands. Such involvement cannot be documented using the Ann Arbor classification system.

[FIGURE 1 OMITTED]

RESULTS

Under the auspices of the American Joint Committee on Cancer, we have developed a staging system to overcome the limitations of the Ann Arbor system. (26) This new system uses the standard tumor, node, and metastasis (TNM) format. It is based on published evidence and the clinical experience of the authors. Our OAL staging system (Table) aims to define disease extent more precisely and to facilitate future studies identifying clinical and histomorphologic features of prognostic significance. This system is not intended for secondary lymphomatous involvement of ocular adnexa or for intraocular lymphomas. It must be emphasized that our OAL staging system should be used in conjunction with histologic subtyping according to the latest World Health Organization lymphoma classification. (8)

The T stage defines the lymphomatous involvement of the ocular adnexa. It essentially subdivides the stage IE of the Ann Arbor classification into finer subgroups, allowing for better documentation of disease extent. T1 categorizes conjunctival OALs according to whether they are bulbar (T1a; Figure 2), or nonbulbar (T1b; ie, confined to fornix and/or caruncle). Tumors that involve both bulbar and nonbulbar conjunctiva are placed in the T1c category (Figure 3). These categories are based on evidence indicating that nonbulbar conjunctival involvement carries a worse prognosis. Multifocal tumors are identified using the prefix m. Similarly, the prefix b indicates bilateral ocular adnexal disease (Figure 4). These prefixes can be applied to any T stage.

Stage T2 defines any OALs involving the orbit, whether or not the conjunctiva is affected. Several studies have shown that the prognosis is worse with orbital involvement than with lymphoma confined to conjunctiva (Figure 4).18-20 An orbital tumor is categorized as anterior and posterior, according to its predominant location in relation to the equator of the globe. The anterior orbit is defined as the area between the orbital septum and the equator of the globe. The posterior orbit is defined as the area posterior to the equator of the globe, extending to the orbital apex. This distinction is based on one of the authors' unpublished data (J.R., 2008) and will be investigated by outcomes analyses. Without such tentative categorization, future investigations evaluating the prognostic value of T2 subgroups would be more difficult. Ocular adnexal lymphomas infiltrating the nasolacrimal drainage system, but not reaching the nasopharynx, are staged as T2d.

Stage T3 indicates OAL infiltration of preseptal eyelid tissues (ie, tissues anterior to the orbital septum, such as dermis, orbicularis muscle, or eyelid skin) as defined previously (Figure 5). (27) There is much evidence showing that preseptal eyelid involvement is associated with a worse prognosis than disease confined to conjunctiva and/or orbit. (3-5,15,18,19,28) Tumors are categorized as T3 irrespective of any such conjunctival and/or orbital involvement.

Stage T4 refers to tumor invasion of bony and soft-tissue structures beyond the ocular adnexa, including the periosteum, bone, nasopharynx, the adjacent sinuses, and the intracranial cavity (Figure 6). These advanced stages are usually seen with high-grade lymphomas, which behave aggressively (eg, diffuse large B-cell lymphomas, mantle cell lymphomas, and T/NK cell lymphomas). (9,10,29,30)

Lymph node involvement of OAL at diagnosis is documented using the N stage. The regional lymph nodes of the ocular adnexa include the submandibular, preauricular, and cervical lymph nodes. Distant nodes include "central" nodes, located in the trunk (eg, mediastinal and para-aortic nodes) and "peripheral" nodes at other distant sites not draining the ocular adnexa (eg, popliteal lymph nodes). The different substages of N indicate whether the lymph node involvement is local (ipsilateral, contralateral, bilateral), central, or peripheral.

The M stage documents involvement of an extranodal site distant to the ocular adnexa as well as bone marrow infiltration (Figure 7). The most common metastatic sites of OAL include salivary glands, gastrointestinal tract, lung, and liver. Lymphomatous infiltration of these organs can be recorded at either the time of first diagnosis or subsequently, in which case the term Ml is used. Bone marrow infiltration occurs in up to 30% of patients with OAL. (2,4) This infiltration can occur in different patterns (eg, micronodular, paratrabecular, or diffuse interstitial) and should be documented as M2.

[FIGURE 2 OMITTED]

[FIGURE 3 OMITTED]

[FIGURE 4 OMITTED]

[FIGURE 5 OMITTED]

[FIGURE 6 OMITTED]

[FIGURE 7 OMITTED]

COMMENT

This is the first TNM staging system for OAL. (26) It describes such tumors more precisely than the Ann Arbor system. The stages we have defined are based on published evidence, much of which has been corroborated by multiple, independent studies, some with large patient numbers. (2-5,15-19,31-35) The T2a and T2b stages, documenting the extent of orbital involvement, are not based on published evidence, but rather, on extensive experience, but should facilitate future evaluation of these categories. Intuitively, one would expect that more extensive orbital involvement would reflect more aggressive or more advanced disease and, hence, a worse prognosis.

A weakness of our staging system is that it has not been validated on a large cohort of patients; however, such studies--both retrospective and prospective--are in progress. Encouragingly, our proposed TNM staging system for OAL has been ratified by both the International Union against Cancer and the College of American Pathologists (K. T. Bradley, D. A. Arber, M. Brown, et al, unpublished data, 2008).

It must be emphasized that this proposed staging system is for primary OAL only and is not intended for intraocular lymphomas. It is acknowledged that controversy does exist about some patients with extensive systemic disease as to whether the lymphoma manifestation in the ocular adnexa is primary or secondary. Careful analysis of the clinical history and ascertaining the presence or absence of any previous evidence of lymphomatous disease elsewhere usually enables clarity in such cases.

Future plans include the incorporation of nonclinical data with the aim of identifying biomarkers of prognostic relevance. Such data might include histomorphologic lymphoma subtyping, immunohistochemical indicators of cell proliferation (eg, Ki-67), as well as cytogenetic (36-39) and molecular genetic information. (40,41) Clinical data, such as age, general condition, and serum markers (eg, lactate dehydrogenase level) will be merged with our TNM scores to derive prognostic indices, providing more predictive information for the individual patient.

CONCLUSIONS

Current staging systems for NHL are not useful for the clinical staging of OALs. A user-friendly staging system for OAL would improve communication about the stage of disease, selection of appropriate management, standardization of enrollment and response criteria in clinical trials, and collection/analysis of prospective survival data. The proposed American Joint Committee on Cancer-International Union Against Cancer staging system for OAL is the first specialized TNM-based staging system of ocular lymphomas. It allows for analysis of site-specific factors not addressed by previous systems. The TNM OAL staging system is currently an anatomic documentation of disease extent but will, in the future, incorporate additional prognostic information (eg, clinical, biologic, and molecular biologic data).

We sincerely thank Stefan Seregard, MD, and James O. Armitage, MD, for their involvement in the design of, and discussions about, the TNM staging system for OAL as well as proofreading the TNM chapter in the 7th edition of the AJCCs Cancer Staging Handbook (in press).

References

(1.) White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma: a clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology. 1995;102(12):1994-2006.

(2.) Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. Ophthalmology. 1998;105(8):1430 1441.

(3.) Jakobiec FA, Knowles DM. An overview of ocular adnexal lymphoidtumors. Trans Am Ophthalmol Soc. 1989;87:420-442 discussion 442-444.

(4.) Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84(8):907-913.

(5.) Coupland SE, Hellmich M, Auw-Haedrich C, Lee W, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004;242(2):130-145.

(6.) Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108(5):1451-1460.

(7.) Jakobiec FA. Ocular adnexal lymphoid tumors: progress in need of clarification. Am J Ophthalmol. 2008;145(6):941-950.

(8.) Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:214. World Health Organization Classification of Tumours; vol 2.

(9.) Coupland SE, Foss HD, Assaf C, et al. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. Ophthalmology. 1999; 106(11):2109-2120.

(10.) Woog JJ, Kim YD, Yeatts RP, et al. Natural Killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology. 2006;113(1):140-147.

(11.) Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31(11):1860-1861.

(12.) Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas [in German]. Strahlentherapie. 1977;153(4):218-221.

(13.) Ruskone-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon AC, de Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003; 52(6):912-916.

(14.) Gardiner JA, White VA, Gascoyne RD, Rootman J. Histopathologic, immunophenotypic and genotypic analyses in ocular adnexal lympho-proliferative disorders. Aust N Z J Ophthalmol. 1992;20(3):247-251.

(15.) Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170-184.

(16.) Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol. 2007;125(12):1663-1667.

(17.) Plaisier MB, Sie-Go DM, Berendschot TT, Petersen EJ, Mourits MP. Ocular adnexal lymphoma classified using the WHO classification: not only histology and stage, but also gender is a predictor of outcome. Orbit. 2007;26(2):83-88.

(18.) Knowles DM, Jakobiec FA, McNally L, Burke JS. Lymphoid hyperplasia and malignantlymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol. 1990;21(9):959-973.

(19.) Johnson TE, Tse DT, Byrne GE Jr, et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg. 1999;15(3):171-179.

(20.) Shields CL, Shields JA, Carvalho C, Rundle P, Smith AF. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108(5):979-984.

(21.) Wanyura H, Uliasz M, Kaminski A, Samolczyk-Wanyura D, Smolarz-Wojnowska A. Diagnostic difficulties and treatment of non-Hodgkin lymphoma of the orbit. J Craniomaxillofac Surg. 2007;35(1):39-47.

(22.) Martinet S, Ozsahin M, Belkacemi Y, etal. Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55(4):892-898.

(23.) Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lympho-proliferative disease. Ophthalmology. 2006;1 13(12):2331-2337.

(24.) Roe RH, Finger PT, Kurli M, Tena LB, Iacob CE. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lympho ma. Ophthalmology. 2006;113(10):1854-1858.

(25.) Meunier J, Rouic L, Dendale R, et al. Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors. Leuk Lymphoma. 2006;47(7):1295-1305.

(26.) Coupland SE, White V, Rootman J, et al. TNM Staging of Ocular Adnexal Lymphomas. In: Edge SE, Byrd DR, Carducci MA, Compton CA, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.

(27.) Knowles DM, ed. Neoplastic Hematopathology. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001.

(28.) Sigelman J, Jakobiec FA. Lymphoid lesions of the conjunctiva: relation of histopathology to clinical outcome. Ophthalmology. 1978;85(8):818-843.

(29.) Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J, White VA. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology. 2005; 112(1):114-119.

(30.) Coupland SE, Hummel M, Stein H. Ocular adnexal lymphomas: five case presentations and a review of the literature. Surv Ophthalmol. 2002;47(5):470 490.

(31.) Medeiros LJ, Harris NL. Lymphoid infiltrates of the orbit and conjunctiva: amorphologic and immunophenotypic study of 99 cases. Am J Surg Pathol. 1989; 13(6):459-471.

(32.) Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Graff A, Buchen R, Witschel H. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Br J Ophthalmol. 2001;85(1):63-69.

(33.) McKelvie PA, McNab A, Francis IC, Fox R, O'Day J. Ocular adnexal lympho-proliferative disease: a series of 73 cases. Clin Experiment Ophthalmol. 2001; 29(6):387-393.

(34.) Sharara N, Holden JT, Wojno TH, Feinberg AS, Grossniklaus HE. Ocular adnexal lymphoid proliferations: clinical, histologic, flow cytometric, and molecular analysis of forty-three cases. Ophthalmology. 2003;110(6):1245-1254.

(35.) Charlotte F, Doghmi K, Cassoux N, et al. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. Virchows Arch. 2006;448(4):506-516.

(36.) Ness GO, Lybsek H, Arnes J, Rodahl E. Chromosomal imbalances in lymphoid tumors of the orbit. Invest Ophthalmol Vis Sci. 2002;43(1):9-14.

(37.) Matteucci C, Galieni P, Leoncini L, et al. Typical genomic imbalances in primary MALT lymphoma of the orbit. JPathol. 2003;200(5):656-660.

(38.) Tanimoto K, Sekiguchi N, Yokota Y, etal. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer. 2006; 6:249.

(39.) Ruiz A, Reischl U, Swerdlow SH, et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am J Surg Pathol. 2007;31(5):792-802.

(40.) Kim WS, Honma K, Karnan S, et al. Genome-wide array-based comparative-genomic hybridization of ocular marginal zoneb cell lymphoma: comparison with pulmonary and nodal marginal zoneB cell lymphoma. Genes-Chromosomes Cancer. 2007;46(8):776-783.

(41.) Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3 is the target gene of chromosomal band 6q23.3-q.24.1 loss in ocular adnexal marginal zone B-cell lymphoma. Genes Chromosomes Cancer. 2008;47(1):1-7.

Sarah E. Coupland, MBBS, PhD; Valerie A. White, MD, MHSc; Jack Rootman, MD; Bertil Damato, MD, PhD; Paul T. Finger, MD

Accepted for publication April 3, 2009.

From the Department of Pathology, University of Liverpool, Liverpool, England (Dr Coupland); the Departments of Pathology and Laboratory Medicine (Dr White) and Ophthalmology (Dr Rootman), Vancouver General Hospital, Vancouver, Canada; the St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, England (Dr Damato); and The New York Eye Cancer Center, New York City (Dr Finger).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Sarah E. Coupland, MBBS, PhD, Department of Pathology, School of Cancer Studies, University of Liverpool, Duncan Bldg, Daulby St, Liverpool L69 3GA, England (e-mail: s.e.coupland@liverpool. ac.uk).
TNM Clinical Staging for Ocular Adnexal Lymphomas (OALs) (a)

Primary tumor (T)

TX   Lymphoma extent not specified

T0   No evidence of lymphoma

T1   Lymphoma involving the conjunctiva alone without orbital
      involvement
  T1a  Bulbar conjunctiva only
  T1b  Palpebral conjunctiva [+ or -] fornix [+ or -] caruncle
  T1c  Bulbar and nonbulbar conjunctival involvement

T2   Lymphoma with orbital involvement [+ or -] any conjunctival
      involvement
  T2a  Anterior orbital involvement, (b) but no lacrimal gland
        involvement ([+ or -] conjunctival disease)
  T2b  Anterior orbital involvement with lacrimal gland involvement
        ([+ or -] conjunctival disease)
  T2c  Posterior orbital involvement ([+ or -] conjunctival
        involvement [+ or -] any extraocular muscle involvement)
  T2d  Nasolacrimal drainage system involvement ([+ or -] conjunctival
        involvement but not including nasopharynx)

T3   Lymphoma with preseptal eyelid involvement (23,c) [+ or -]
      orbital involvement [+ or -] any conjunctival involvement

T4   Orbital adnexal lymphoma extending beyond orbit to adjacent
      structures, such as bone and brain
  T4a  Involvement of nasopharynx
  T4b  Osseous involvement (including periosteum)
  T4c  Involvement of maxillofacial, ethmoidal [+ or -] frontal sinuses
  T4d  Intracranial spread

Lymph node involvement (N) (d)

NX   Involvement of lymph nodes not assessed
N0   No evidence of lymph node involvement
N1   Involvement of ipsilateral regional lymph nodesd
N2   Involvement of contralateral or bilateral regional lymph nodes
N3   Involvement of peripheral lymph nodes not draining ocular
      adnexal region
N4   Involvement of central lymph nodes

Distant metastasis (M)

MX   Dissemination of lymphoma not assessed
M0   No evidence of involvement of other extranodal sites
M1   Lymphomatous involvement in other organs recorded either at first
      diagnosis or subsequently
  M1a  Noncontiguous involvement of tissues or organs external to the
        ocular adnexa (eg, parotid glands, submandibular gland, lung,
        liver, spleen, kidney, breast)
  M1b  Lymphomatous involvement of the bone marrow
  M1c  Both M1a and M1b involvement

(a) Used with the permission of the American Joint Committee on Cancer
(AJCC), Chicago, Illinois. The original source for this material is the
AJCC Cancer Staging Manual, Seventh Edition (2009) published by
Springer Science and Business Media LLC, www.springerlink.com.

(b) The anterior orbit is defined as the area between the orbital
septum and the equator of the globe. The posterior orbit is defined as
the area posterior to the equator of the globe, extending to the orbital
apex.

(c) Eyelid involvement is said to exist when the OAL infiltrates
preseptal tissues (ie, tissues anterior to the orbital septum).

(d) Regional lymph nodes, which include the preauricular (parotid),
submandibular, and cervical lymph nodes.
Gale Copyright: Copyright 2009 Gale, Cengage Learning. All rights reserved.